The terms “personalized” or “precision” medicine are being used commonly in some branches of medicine but have yet to be widely adopted in vascular surgery. Despite this, personalized vascular therapy occurs on a daily basis in every vascular specialist’s office as we strive to make informed recommendations at the individual patient level. The following is a description of several of the areas where advances in personalized vascular care have been achieved, including custom devices, personalized predictions, pharmacogenetics and surgicogenetics.
Collins FS and Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793–795.
2.
HamburgMACollinsFS. The path to personalized medicine. N Engl J Med2010; 363: 301–304.
3.
MirnezamiRNicholsonJDarziA. Preparing for precision medicine. N Engl J Med2012; 366: 489–491.
4.
BeggsADDilworthMP. Surgery in the era of the ‘omics revolution. Br J Surg2015; 102: e29–e40.
5.
National Research Council. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press, 2011. DOI: 10.17226/13284.
6.
FinlayAJohnsonMForbesTL. Surgically relevant aortic arch mapping using computed tomography. Ann Vasc Surg2012; 26: 483–490.
7.
LeottaDFStarnesBW. Custom fenestration templates for endovascular repair of juxtarenal aortic aneurysms. J Vasc Surg2015; 61: 1637–1641.
8.
MorrisAHIoannidisJP. Limitations of medical research and evidence at the patient-clinician encounter scale. Chest2013; 143: 1127–1135.
9.
IoannidisJPKhouryMJ. Are randomized trials obsolete or more important than ever in the genomic era?Genome Med2013; 5: 32–32.
10.
DorresteijnJAVisserenFLRidkerPM. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ2011; 343: d5888–d5888.
11.
FaizerRDeRoseGLawlorDK. Objective scoring systems of medical risk: a clinical tool for selecting patients for open or endovascular abdominal aortic aneurysm repair. J Vasc Surg2007; 45: 1102–1108.
12.
GreenhalghRMBrownLCKwongGP. participants Et. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet2004; 364: 843–848.
13.
ScottSA. Personalizing medicine with clinical pharmacogenetics. Genet Med2011; 13: 987–995.
14.
KarnabatidisDSpiliopoulosSPastromasG. Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing. Cardiovasc Intervent Radiol2014; 37: 631–638.
15.
GuoBTanQGuoD. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg2014; 60: 993–1001.
16.
ConteMSOwensCDBelkinM. A single nucleotide polymorphism in the p27(Kip1) gene is associated with primary patency of lower extremity vein bypass grafts. J Vasc Surg2013; 57: 1179–1185.
